No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions – Results from a randomised blinded trial

Sharp, Lena; Finnilä, Kristina; Johansson, Hemming; Abrahamsson, Marie; Hatschek, Thomas; Bergenmar, Mia

doi:10.1016/j.ejon.2012.11.003

Cited by 81 publications

(86 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 3 lists the randomized studies on the prevention of acute radiation skin reactions in patients with breast cancer receiving radiotherapy in last 5 years. 4,[17][18][19][20][21][22][23][24][25][26][27][28] Randomized controlled studies have generated mostly negative results for use of skin care products in preventing or treating radiation dermatitis. Remarkably, patients receiving topical corticosteroids (mometasone furoate and betamethasone) during radiotherapy might experience reduced acute skin toxicity compared with placebo or moisturizing creams according to the result of three doubleblind studies with a larger population.…”

Section: Discussionmentioning

confidence: 99%

Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy

Zhao¹,

Zhu²,

Li³

et al. 2016

BJR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy

Zhao¹,

Zhu²,

Li³

et al. 2016

BJR

View full text Add to dashboard Cite

“…Randomized controlled studies of skin care products compared with placebo had generally been negative in preventing or treating radiation dermatitis [15–19]. Recently, Miller et al has suggested that topical monetasone reduces ≥ Grade 3 radiation-induced dermatitis and alleviates the symptoms.…”

Section: Discussionmentioning

confidence: 99%

Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy

Zhu

Chen³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

There are few effective treatment options for radiation-induced dermatitis in breast cancer patients. We conducted a single-arm trial to tested the hypothesis that topical epigallocatechin-3-gallate (EGCG) is effective against radiation-induced dermatitis in breast cancer patients undergoing radiotherapy. Forty-nine patients participated in this study. The patients underwent mastectomy followed by adjuvant radiotherapy. Topical EGCG was applied daily, starting when grade I dermatitis appeared and ending two weeks after radiotherapy. The maximum dermatitis observed during the EGCG treatment was as follows: Grade 1 toxicity, 71.4% (35 patients); grade 2 toxicity, 28.6% (14 patients); there were no patients with grade 3 or 4 toxicity. The majority of the radiation-induced dermatitis was observed 1 week after the end of radiotherapy. EGCG reduced the pain in 85.7% of patients, burning-feeling in 89.8%, itching in 87.8%, pulling in 71.4%, and tenderness in 79.6%. These findings suggest topical EGCG may be an effective treatment for radiation-induced dermatitis and has acceptable toxicity.

show abstract

“…However, while qualitatively well recognized [26], QOL studies are lacking on radiation-induced dermatitis and other skin symptoms in breast cancer patients [27]. Recently completed prospective trials evaluating QOL [4] and topical applications for alleviation of dermatitis symptoms [28,29] did not use repeated measures analyses, instead reporting a detailed, generalized model for analyzing long-term repeated measures data [4]. The potential application of repeated measures analyses in dermatitis-related symptom control trials of breast and head and neck cancers is emerging.…”

Section: Discussionmentioning

confidence: 99%

Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance])

Sio

Atherton

Birckhead

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

Purpose Radiotherapy-related dermatological toxicities over time have not been well quantified. We examined during and immediately following radiation therapy skin toxicities over time in a randomized study of mometasone furoate vs placebo during breast radiotherapy. Material and Methods Patients with breast cancer undergoing radiotherapy to the breast or chest wall were randomized. Symptoms related to skin toxicity were addressed weekly using provider-reported Common Terminology Criteria for Adverse Events (CTCAE v3.0) and 4 patient-reported outcomes (PRO) surveys. We applied repeated measures and risk analysis methodologies. Results 176 patients were enrolled. By CTCAE significant differences favoring mometasone were detected over time in all toxicities except skin striae, atrophy, and infection. Statistically significant differences between arms at baseline but not over time occurred for all Linear Analog Self-Assessment assessments. Statistically significant differences occurred for all symptoms in the temporal profile of symptoms as measured by PRO surveys (all P<.001). Conclusions The use of longitudinal methods enhanced the ability of PRO tools to detect differences between study arms. Our results strengthened the conclusions of the original report that mometasone reduced acute skin toxicities. PRO surveys can accurately assess patients’ experiences of symptom type and intensity over time and should be included in future clinical trials.

show abstract

No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions – Results from a randomised blinded trial

Cited by 81 publications

References 22 publications

Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy

Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy

Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy

Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance])

Contact Info

Product

Resources

About